Therapeutic antibodies against cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

36 citing papers in PubMed.

1. A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells.mAbs
   Trial
2. Global Disproportionality Analysis of Adverse Event Reports on Interstitial Lung Diseases for Cancer-Targeted Therapies, 1968-2024.Respirology (Carlton, Vic.) · 2026
   Article
3. Nanobody-Based Drug Delivery: Emerging Strategies for Targeted Cancer Therapy.International journal of nanomedicine · 2026
   Review
4. Advances in Peptidomimetics for Next-Generation Therapeutics: Strategies, Modifications, and Applications.Chemical reviews · 2025
   Review
5. Single-domain antibodies as therapeutics for solid tumor treatment.Acta pharmaceutica Sinica. B · 2024
   Review
6. Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study.Oncology · 2024
   Article
7. Targeted Alpha Therapy (TAT) with Single-Domain Antibodies (Nanobodies).Cancers · 2023
   Review
8. Small extracellular vesicle-mediatedCancer biology & therapy · 2022
   Article
9. Fc Receptor Variants and Disease: A Crucial Factor to Consider in the Antibody Therapeutics in Clinic.International journal of molecular sciences · 2021
   Review
10. Strategies to enhance monoclonal antibody uptake and distribution in solid tumors.Cancer biology & medicine · 2021
    Review
11. Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers.Nano-micro letters · 2021
    Review
12. Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment.Scientific reports · 2021
    Article
13. Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities.Cancers · 2021
    Review
14. Applications of Nanoparticle-Antibody Conjugates in Immunoassays and Tumor Imaging.The AAPS journal · 2021
    Review
15. Punicalagin promotes the apoptosis in human cervical cancer (ME-180) cells through mitochondrial pathway and by inhibiting the NF-kB signaling pathway.Saudi journal of biological sciences · 2020
    Article
16. Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Article
17. Immuno-PET to Optimize the Dose of Monoclonal Antibodies for Cancer Therapy: How Much Is Enough?Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Article
18. Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells.JCI insight · 2019
    Article
19. Expression and Evaluation of HuscFv Antibody -PE40 Immunotoxin for Target Therapy of EGFR-Overexpressing Cancers.Iranian journal of biotechnology · 2018
    Article
20. N-terminal α-amino group modification of antibodies using a site-selective click chemistry method.mAbs · 2018
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

Abstract

Indexed as